These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33007330)

  • 1. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
    Shi Y; Ma Z; Cheng Q; Wu Y; Parris AB; Kong L; Yang X
    Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118877. PubMed ID: 33007330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
    Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
    Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
    Yang Y; Chan JY; Temiz NA; Yee D
    Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.
    Meyer K; Albaugh B; Schoenike B; Roopra A
    Mol Cell Biol; 2015 Sep; 35(17):2991-3004. PubMed ID: 26100015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
    Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
    Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
    Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
    Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
    Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
    Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
    Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
    Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
    Tandon M; Chen Z; Othman AH; Pratap J
    Oncogene; 2016 Sep; 35(36):4730-40. PubMed ID: 26804175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1.
    Cesarone G; Edupuganti OP; Chen CP; Wickstrom E
    Bioconjug Chem; 2007; 18(6):1831-40. PubMed ID: 17922544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells.
    Cesarone G; Garofalo C; Abrams MT; Igoucheva O; Alexeev V; Yoon K; Surmacz E; Wickstrom E
    J Cell Biochem; 2006 May; 98(2):440-50. PubMed ID: 16440325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 18. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
    de Miranda LBL; Lima K; Coelho-Silva JL; Traina F; Kobayashi SS; Machado-Neto JA
    Sci Rep; 2022 Oct; 12(1):17092. PubMed ID: 36224313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.